Evidence map›Paper›PMID 29572553›Full record

ArticleScientific reports2018

Galantamine anti-colitic effect: Role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways.

Shakeeb A Wazea, Walaa Wadie, Ashraf K Bahgat, Hanan S El-Abhar

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 72 citations in OpenAlex.

  1. Application of 18Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Frontiers in microbiology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Cardiovascular Outcomes Associated with Cholinesterase Inhibitor Use in Individuals at High Cardiovascular Risk.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Cholinergic Mechanisms in Gastrointestinal Neoplasia.International journal of molecular sciences · 2024
    Review
  15. Article
  16. Sterols in Inflammatory Diseases: Implications and Clinical Utility.Advances in experimental medicine and biology · 2024
    Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shakeeb A WazeaDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Walaa WadieDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. walaa.wadie@pharma.cu.edu.eg.
Ashraf K BahgatDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Hanan S El-AbharDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vagal stimulation controls systemic inflammation and modulates the immune response in different inflammatory conditions, including inflammatory bowel diseases (IBD). The released acetylcholine binds to alpha-7 nicotinic acetylcholine receptor (α7 nAChR) to suppress pro-inflammatory cytokines. This provides a new range of potential therapeutic approaches for controlling inflammatory responses. The present study aimed to assess whether galantamine (Galan) anti-inflammatory action involves α7 nAChR in a 2,4,6-trinitrobenzene sulfonic acid (TNBS) model of colitis and to estimate its possible molecular pathways. Rats were assigned into normal, TNBS, sulfasalazine (Sulfz), Galan treated (10 mg/kg), methyllycaconitine (MLA; 5.6 mg/kg), and MLA + Galan groups. Drugs were administered orally once per day (11 days) and colitis was induced on the 8

Indexed as

Inflammatory Bowel Diseasesalpha7 Nicotinic Acetylcholine ReceptorAnimalsGalantamineJanus KinasesMaleNF-kappa BProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2RatsRats, WistarReceptor for Advanced Glycation End ProductsSignal TransductionSTAT3 Transcription FactorAger protein, ratalpha7 Nicotinic Acetylcholine ReceptorBcl2 protein, ratGalantamineJanus KinasesNF-kappa BProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2Receptor for Advanced Glycation End ProductsStat3 protein, ratSTAT3 Transcription Factor

Identifiers

PMID29572553
PMCPMC5865178
OpenAlexW2805440144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.